Latest Insider Transactions at Quanterix Corp (QTRX)
This section provides a real-time view of insider transactions for Quanterix Corp (QTRX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Quanterix Corp to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Quanterix Corp's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 04
2022
|
David C. Duffy SVP R&D and CTO |
SELL
Open market or private sale
|
Direct |
3,266
-5.33%
|
$97,980
$30.91 P/Share
|
|
Feb 02
2022
|
John J Fry General Counsel & Secretary |
SELL
Open market or private sale
|
Direct |
371
-0.58%
|
$11,501
$31.68 P/Share
|
|
Feb 02
2022
|
E Kevin Hrusovsky Executive Chairman |
SELL
Open market or private sale
|
Direct |
589
-0.03%
|
$18,259
$31.68 P/Share
|
|
Feb 02
2022
|
Dawn Mattoon Sr. VP, Diagnostics |
SELL
Open market or private sale
|
Direct |
267
-0.35%
|
$8,277
$31.68 P/Share
|
|
Feb 02
2022
|
Mark T. Roskey SVP, Strategic Partnerships |
SELL
Open market or private sale
|
Direct |
166
-0.36%
|
$5,146
$31.68 P/Share
|
|
Jan 31
2022
|
David C. Duffy SVP R&D and CTO |
SELL
Open market or private sale
|
Direct |
3,266
-5.06%
|
$97,980
$30.0 P/Share
|
|
Jan 03
2022
|
David C. Duffy SVP R&D and CTO |
BUY
Exercise of conversion of derivative security
|
Direct |
41,246
+21.74%
|
$82,492
$2.71 P/Share
|
|
Jan 03
2022
|
David R Walt |
BUY
Grant, award, or other acquisition
|
Direct |
2,668
+0.21%
|
-
|
|
Jan 03
2022
|
Laurie J Olson |
BUY
Grant, award, or other acquisition
|
Direct |
2,668
+27.02%
|
-
|
|
Jan 03
2022
|
Paul M Meister |
BUY
Grant, award, or other acquisition
|
Direct |
2,992
+7.86%
|
$62,832
$21.21 P/Share
|
|
Jan 03
2022
|
Sarah E. Hlavinka |
BUY
Grant, award, or other acquisition
|
Direct |
2,948
+8.67%
|
$61,908
$21.21 P/Share
|
|
Jan 03
2022
|
Dawn Mattoon Sr. VP, Diagnostics |
SELL
Open market or private sale
|
Direct |
355
-0.93%
|
$14,555
$41.91 P/Share
|
|
Jan 03
2022
|
Mark T. Roskey SVP, Strategic Partnerships |
SELL
Open market or private sale
|
Direct |
149
-0.64%
|
$6,109
$41.91 P/Share
|
|
Jan 03
2022
|
E Kevin Hrusovsky Executive Chairman |
SELL
Open market or private sale
|
Direct |
3,715
-0.42%
|
$152,315
$41.91 P/Share
|
|
Jan 03
2022
|
John J Fry General Counsel & Secretary |
SELL
Open market or private sale
|
Direct |
352
-1.09%
|
$14,432
$41.91 P/Share
|
|
Jan 03
2022
|
Martin D Madaus |
BUY
Grant, award, or other acquisition
|
Direct |
3,095
+7.58%
|
$64,995
$21.21 P/Share
|
|
Jan 03
2022
|
Keith Crandell |
BUY
Grant, award, or other acquisition
|
Direct |
2,975
+1.24%
|
$62,475
$21.21 P/Share
|
|
Dec 29
2021
|
David C. Duffy SVP R&D and CTO |
SELL
Open market or private sale
|
Direct |
1,667
-6.68%
|
$66,680
$40.71 P/Share
|
|
Dec 01
2021
|
John J Fry General Counsel & Secretary |
SELL
Open market or private sale
|
Direct |
350
-0.54%
|
$14,000
$40.63 P/Share
|
|
Dec 01
2021
|
Dawn Mattoon Sr. VP, Diagnostics |
SELL
Open market or private sale
|
Direct |
353
-0.46%
|
$14,120
$40.63 P/Share
|
|
Dec 01
2021
|
Mark T. Roskey SVP, Strategic Partnerships |
SELL
Open market or private sale
|
Direct |
147
-0.31%
|
$5,880
$40.63 P/Share
|
|
Dec 01
2021
|
E Kevin Hrusovsky Executive Chairman |
SELL
Open market or private sale
|
Direct |
3,710
-0.21%
|
$148,400
$40.63 P/Share
|
|
Nov 19
2021
|
David C. Duffy SVP R&D and CTO |
SELL
Open market or private sale
|
Direct |
1,667
-6.26%
|
$75,015
$45.54 P/Share
|
|
Nov 18
2021
|
Keith Crandell |
BUY
Other acquisition or disposition
|
Direct |
9,318
+7.48%
|
-
|
|
Nov 18
2021
|
Keith Crandell |
SELL
Other acquisition or disposition
|
Indirect |
290,250
-100.0%
|
-
|
|
Nov 16
2021
|
Keith Crandell |
BUY
Other acquisition or disposition
|
Direct |
9,952
+8.59%
|
-
|
|
Nov 16
2021
|
Keith Crandell |
SELL
Other acquisition or disposition
|
Indirect |
310,000
-51.65%
|
-
|
|
Nov 10
2021
|
E Kevin Hrusovsky Executive Chairman |
SELL
Open market or private sale
|
Direct |
5,000
-0.18%
|
$275,000
$55.13 P/Share
|
|
Nov 05
2021
|
Dawn Mattoon Sr. VP, Diagnostics |
SELL
Open market or private sale
|
Direct |
8,535
-9.08%
|
$486,495
$57.82 P/Share
|
|
Nov 05
2021
|
Dawn Mattoon Sr. VP, Diagnostics |
BUY
Exercise of conversion of derivative security
|
Direct |
10,718
+18.5%
|
$203,642
$19.12 P/Share
|
|
Nov 04
2021
|
Dawn Mattoon Sr. VP, Diagnostics |
SELL
Open market or private sale
|
Direct |
1
-0.0%
|
$57
$57.0 P/Share
|
|
Nov 02
2021
|
John J Fry General Counsel & Secretary |
SELL
Open market or private sale
|
Direct |
331
-0.5%
|
$17,212
$52.77 P/Share
|
|
Nov 02
2021
|
E Kevin Hrusovsky Executive Chairman |
SELL
Open market or private sale
|
Direct |
3,505
-0.19%
|
$182,260
$52.77 P/Share
|
|
Nov 02
2021
|
Dawn Mattoon Sr. VP, Diagnostics |
SELL
Open market or private sale
|
Direct |
333
-0.45%
|
$17,316
$52.77 P/Share
|
|
Nov 02
2021
|
Mark T. Roskey SVP, Strategic Partnerships |
SELL
Open market or private sale
|
Direct |
139
-0.3%
|
$7,228
$52.77 P/Share
|
|
Oct 22
2021
|
E Kevin Hrusovsky Executive Chairman |
SELL
Open market or private sale
|
Direct |
5,000
-0.18%
|
$250,000
$50.94 P/Share
|
|
Oct 15
2021
|
David C. Duffy SVP R&D and CTO |
SELL
Open market or private sale
|
Direct |
1,667
-5.89%
|
$85,017
$51.47 P/Share
|
|
Oct 01
2021
|
Paul M Meister |
BUY
Grant, award, or other acquisition
|
Direct |
269
+1.89%
|
$13,719
$51.18 P/Share
|
|
Oct 01
2021
|
Martin D Madaus |
BUY
Grant, award, or other acquisition
|
Direct |
354
+2.25%
|
$18,054
$51.18 P/Share
|
|
Oct 01
2021
|
Sarah E. Hlavinka |
BUY
Grant, award, or other acquisition
|
Direct |
232
+1.91%
|
$11,832
$51.18 P/Share
|
|
Oct 01
2021
|
Mark T. Roskey SVP, Strategic Partnerships |
SELL
Open market or private sale
|
Direct |
143
-0.6%
|
$7,293
$51.2 P/Share
|
|
Oct 01
2021
|
Dawn Mattoon Sr. VP, Diagnostics |
SELL
Open market or private sale
|
Direct |
342
-0.92%
|
$17,442
$51.2 P/Share
|
|
Oct 01
2021
|
John J Fry General Counsel & Secretary |
SELL
Open market or private sale
|
Direct |
340
-1.02%
|
$17,340
$51.2 P/Share
|
|
Oct 01
2021
|
Keith Crandell |
BUY
Grant, award, or other acquisition
|
Direct |
254
+0.26%
|
$12,954
$51.18 P/Share
|
|
Oct 01
2021
|
E Kevin Hrusovsky Executive Chairman |
SELL
Open market or private sale
|
Direct |
3,594
-0.39%
|
$183,294
$51.2 P/Share
|
|
Sep 30
2021
|
E Kevin Hrusovsky Executive Chairman |
SELL
Open market or private sale
|
Direct |
5,000
-0.27%
|
$240,000
$48.38 P/Share
|
|
Sep 22
2021
|
David C. Duffy SVP R&D and CTO |
SELL
Open market or private sale
|
Direct |
1,667
-5.57%
|
$78,349
$47.72 P/Share
|
|
Sep 02
2021
|
E Kevin Hrusovsky Executive Chairman |
SELL
Open market or private sale
|
Direct |
5,000
-0.27%
|
$245,000
$49.95 P/Share
|
|
Sep 01
2021
|
E Kevin Hrusovsky Executive Chairman |
SELL
Open market or private sale
|
Direct |
3,709
-0.2%
|
$185,450
$50.26 P/Share
|
|
Sep 01
2021
|
Dawn Mattoon Sr. VP, Diagnostics |
SELL
Open market or private sale
|
Direct |
353
-0.47%
|
$17,650
$50.26 P/Share
|